Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus EPROSARTAN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus EPROSARTAN MESYLATE.
BENICAR HCT vs EPROSARTAN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Eprosartan mesylate is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, 600 mg once daily. May increase to 800 mg once daily if inadequate response.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life is about 5–9 hours. Clinical context: supports once-daily dosing for hypertension.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Primarily biliary/fecal (≈90% as unchanged drug); renal elimination accounts for ≈7% (mostly unchanged).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB